Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bio-Path Holdings (BPTH) has issued an announcement.
Bio-Path Holdings, Inc. recently announced their presentation of promising data from a Phase 2 study exploring the use of Prexigebersen in treating Acute Myeloid Leukemia. This significant development was shared at the esteemed European Hematology Association Congress, showcasing the company’s progress in the field of cancer treatment.
See more data about BPTH stock on TipRanks’ Stock Analysis page.